YIPF1 Inhibitors
YYIPF1 Inhibitors are a diverse group of compounds that suppress the functional activity of YIPF1 by targeting various cellular processes essential for its role in vesicle trafficking. Brefeldin A and Golgicide A, through their inhibitory effects on ARF and GBF1 respectively, cause disassembly of the Golgi structure, indirectly preventing YIPF1 from carrying out its vesicle trafficking functions. Similarly, Monensin disrupts ion gradients crucial for Golgi function, while Tunicamycin hampers N-linked glycosylation, leading to ER stress and compromised ER-Golgi trafficking, both crucial to YIPF1's role. Cytochalasin D and Swinholide A exert their inhibitory effect by disrupting the actin cytoskeleton, while Nocodazole and Taxol impede microtubule dynamics, all of which are essential for the proper transport of vesicles that YIPF1 facilitates. Dynasore's inhibition of dynamin also hinders vesicle release, thereby indirectly diminishing YIPF1's trafficking capabilities.
Further, GM 6001's suppression of matrix metalloproteinases affects the extracellular matrix and indirectly the cellular processes including vesicle traffic in which YIPF1 is implicated. Latrunculin A's binding to actin monomers and Salubrinal's inhibition of eIF2α dephosphorylation lead to impediments in cytoskeleton dynamics and exacerbated ER stress response, respectively. These disruptions collectively contribute to the indirect inhibition of YIPF1, as the protein's function is contingent on the integrity of these cellular components and processes. By targeting the structural and functional aspects of the cell's transport machinery, these inhibitors collectively ensure that the ability of YIPF1 to facilitate vesicle trafficking is significantly reduced, thereby hindering its function within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus structure by inhibiting the ADP-ribosylation factor (ARF), which is critical for vesicle formation. As YIPF1 is involved in the trafficking and fusion of vesicles in the Golgi, Brefeldin A's action leads to an indirect inhibition of YIPF1 by disassembling the Golgi structure and thus preventing YIPF1 from performing its role in vesicular transport. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin is an ionophore that alters intracellular ion gradients, particularly sodium and hydrogen ions. It disrupts Golgi function and vesicular transport, which are essential for the function of YIPF1 in vesicle trafficking. The disruption of these ion gradients diminishes the functional activity of YIPF1 by preventing proper vesicle formation and transport. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Nocodazole destabilizes microtubules, impairing vesicle transport along these structural elements. As YIPF1 is implicated in vesicular traffic, nocodazole's action on microtubules indirectly diminishes the functional activity of YIPF1 by obstructing the vesicle's transit to and from the Golgi apparatus. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
Cytochalasin D is an inhibitor of actin polymerization, affecting cytoskeletal structure and thus vesicle movement. Since YIPF1 is involved in vesicular transport, the inhibition of actin filaments indirectly hinders YIPF1's function by disrupting the cytoskeletal network necessary for vesicle trafficking. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Dynasore inhibits dynamin, a GTPase important for vesicle scission from membranes. Inhibition of dynamin function indirectly diminishes YIPF1 activity by preventing the release of transport vesicles, which YIPF1 is involved in trafficking. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $187.00 $670.00 | 11 | |
Golgicide A is a specific inhibitor of the Golgi BFA resistance factor 1 (GBF1), a GEF for ARF1, leading to disruption of Golgi structure and function. This indirectly diminishes the functional activity of YIPF1 by impairing the vesicle trafficking processes essential for YIPF1's role in the Golgi. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation in the ER, leading to ER stress and potential disruption of ER-Golgi trafficking. As YIPF1 is involved in this trafficking, tunicamycin's action indirectly inhibits YIPF1 function by hampering the flow of vesicles between the ER and Golgi. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $75.00 $265.00 | 55 | |
GM 6001 is a matrix metalloproteinase inhibitor that can affect the extracellular matrix, in turn influencing cellular processes, including vesicular traffic. The alteration of the extracellular environment indirectly diminishes YIPF1 activity by disrupting cellular interactions and signaling necessary for efficient vesicle transport. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Taxol stabilizes microtubules, which can paradoxically disrupt microtubule dynamics necessary for vesicle transport. The stabilization of microtubules indirectly inhibits YIPF1 function as it relies on dynamic microtubules for its role in vesicle trafficking. | ||||||
Swinholide A, Theonella swinhoei | 95927-67-6 | sc-205914 | 10 µg | $135.00 | ||
Swinholide A sequesters actin dimers and prevents actin polymerization, leading to disruption of the cytoskeletal network. This action indirectly inhibits YIPF1 function by impairing the actin-based movement of vesicles within cells. | ||||||